Skip to content
Connect with us

Health News

FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease

FDA today approved Infilbray (venglustat) tablets, the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg (approximately 33 pounds).

FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease

Published

on

About FDA approves Infilbray

FDA approves Infilbray, shown with a glowing brain and DNA model in a laboratory with silhouetted researchers.
Health News

FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease

FDA today approved Infilbray (venglustat) tablets, the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg (approximately 33 pounds).

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *